Skip to content

The effect of Trichoglocal capsule on the treatment of androgenetic alopecia

Assessing the safety and efficacy of Trichoglocal in the treatment of androgenetic alopecia- Interventional - Randomized controlled clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20250504065592N1
Enrollment
40
Registered
2025-05-25
Start date
2025-05-10
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenetic alopecia. Androgenic alopecia

Interventions

Intervention 1: Intervention group: Trichoglocal capsule (manufactured by Persian Pad Company) once daily with meals along with topical minoxidil 5% solution (manufactured by Pak Darou Company) used e

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The minimum age is 18 years old Male gender Androgenetic alopecia

Exclusion criteria

Exclusion criteria: Renal failure Hepatic failure Previous treatment Wilson disease Major thalasemia Allergy to grape or grape seed

Design outcomes

Primary

MeasureTime frame
The investigator aesthetic improvement scales: dependent variable qualitative/ordinal. The degree of improvement in scalp hair density appearance according to the researcher: 0: no improvement; 1: improvement below 25%; 2: improvement 25 to 49%; 3: improvement 50 to 74%; 4: improvement above 75%. Timepoint: 2 months, 4 months, and 6 months after the start of the study. Method of measurement: Investigator Global Aesthetic Improvement Scales.

Secondary

MeasureTime frame
Patient Global Aesthetic Improvement Scales. Timepoint: 2months, 4months and 6months after the start of the study. Method of measurement: 0: no improvement; 1: improvement below 25%; 2: improvement 25 to 49%; 3: improvement 50 to 74%; 4: improvement above 75%.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Marzbannia

Shiraz University of Medical Sciences

Pegah.m96@gmail.com+98 71 3235 1087

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026